Patel Naimish reported option exercise involving 10,000 derivative units of CRISPR Therapeutics AG on May 28, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Medical Officer
Chief Medical Officer
Filed Jun 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
10,000Restricted Stock Units
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,000Direct
Trade date
May 28, 2026Option exercise
Filed
Jun 1, 2026, 5:35 PM ET4-day reporting delay
Accession
0001193125-26-251817Code M · Transaction 388019
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 29, 2026Sell3,786$55.62−$210,577.32Trade 388018
May 28, 2026Option exercise10,000——Trade 388017
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

CRSP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CRSP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −3.9%1w ago −7.9%1d ago −1.2%
Returns since7d −4.8%30d +2.6%90d +6.5%180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. F3: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.